VORIF TABLETS 50mg
VORIF TABLETS (Voriconazole tablets)
VORIF, containing Voriconazole, demonstrates potent antifungal activity by inhibiting fungal cytochrome P-450 enzymes crucial for ergosterol biosynthesis.
Indicated for invasive aspergillosis, esophageal candidiasis, candidemia, and serious fungal infections, VORIF addresses a spectrum of fungal challenges in both adults and children.
The dosage regimen, including a loading dose for the first 24 hours, ensures rapid achievement of therapeutic plasma concentrations. Subsequent maintenance doses vary based on patient weight.
While generally well-tolerated, users should be mindful of potential adverse reactions, including hypokalemia, visual changes, and, rarely, serious events like pancreatitis or Stevens-Johnson syndrome.
VORIF is contraindicated in cases of hypersensitivity to voriconazole components and when co administered with specific drugs like rifampin, ritonavir, and carbamazepine due to potential interactions
VORIF: Voriconazole Tablets (50mg & 200mg)
Composition:
VORIF TABLETS Each filmcoated
tablet contains Voriconazole 50mg and 200mg respectively
Ferozsons Specifications:
Drug Description:
Voriconazole is a
triazole antifungal agent with the chemical designation (2R,3S)2(2,4difluorophenyl)3(5fluoro4pyrimidinyl)1(1H1,2,4triazol1yl)2butanol
It inhibits fungal cytochrome P450mediated 14 alphalanosterol demethylation, a
crucial step in fungal ergosterol biosynthesis
Clinical Pharmacology:
Mode of Action:
Inhibition of fungal cytochrome P450 enzymes
Pharmacodynamics/Kinetics: Well absorbed
orally, selective for fungal cytochrome P450, hepatic metabolism, bioavailability
of 96%, variable elimination half life
Indications: Invasive
aspergillosis, esophageal candidiasis, candidemia, disseminated Candida
infections, serious fungal infections caused by specific species
Dosage and Administration:
Loading Dose (First
24 hours):
Patients 40kg and above: 400mg every 12 hours
Patients less than 40kg: 200mg every 12 hours
Maintenance Dose
(After the first 24 hours):
Patients 40kg and above: 200mg twice a day
Patients less than 40kg: 100mg twice a day
Recommended Duration:
Minimum of 14 days, with at least 7 days post symptom resolution
Dosing in Special Populations:
Renal Insufficiency:
No dose adjustment necessary
Hepatic Impairment:
Reduce maintenance dosage by 50% in mild to moderate cases; caution in severe
impairment
Elderly: Follow adult
dosing
Teenagers 12 to 14
years (50kg or more): 400mg every 12 hours for the first 24 hours, then 200mg
twice a day
Adverse Reactions:
Common (210%):
Hypokalemia, visual changes, fever, nausea
<2% (Important or
life threatening): Acute tubular necrosis, pancreatitis, respiratory distress
syndrome, Stevens Johnson syndrome, and more
Contraindications:
- Hypersensitivity to
voriconazole or its components - Co-administration with
certain drugs, including rifampin, ritonavir, carbamazepine, and others
Warnings/Precautions:
- Arrhythmias/QT
Prolongation: Caution in patients with risk factors; correct electrolyte
abnormalities - Dermatologic
Reactions: Monitor for photosensitivity; discontinue for severe reactions - Hallucinations:
Mostly with IV formulation; caution is advised
Pregnancy and Lactation:
Pregnancy Risk
Factor: D (Benefit to mother justifies potential risk to the fetus)
Excretion in breast
milk is unknown; not recommended during lactation
Drug Interactions:
Contraindicated with
drugs like rifampin, ritonavir, carbamazepine, etc
Significant
interactions with fluconazole, cimetidine, ranitidine, and others; dosage
adjustment may be necessary
Storage:
Store at 1530 °C in a
dry and dark place Keep out of the reach of children
How Supplied:
Vorif 50mg &
200mg Tablets are available in 1x10's Blister Pack
Please read the contents cautiously before use This package
insert is regularly and timely updated